Cefuroxime Pharmacokinetics in Pediatric Cardiovascular Surgery Patients Undergoing Cardiopulmonary Bypass by Knoderer, Chad A. et al.
Butler University
Digital Commons @ Butler University
Scholarship and Professional Work – COPHS College of Pharmacy & Health Sciences
2011
Cefuroxime Pharmacokinetics in Pediatric
Cardiovascular Surgery Patients Undergoing
Cardiopulmonary Bypass
Chad A. Knoderer
Butler University, cknodere@butler.edu
Sarah A. Saft
Scott G. Walker
Markl D. Rodefeld
Mark W. Turrentine
See next page for additional authors
Follow this and additional works at: http://digitalcommons.butler.edu/cophs_papers
Part of the Cardiology Commons, Pediatrics Commons, and the Pharmacy and Pharmaceutical
Sciences Commons
This Article is brought to you for free and open access by the College of Pharmacy & Health Sciences at Digital Commons @ Butler University. It has
been accepted for inclusion in Scholarship and Professional Work – COPHS by an authorized administrator of Digital Commons @ Butler University.
For more information, please contact fgaede@butler.edu.
Recommended Citation
Knoderer, Chad A.; Saft, Sarah A.; Walker, Scott G.; Rodefeld, Markl D.; Turrentine, Mark W.; Brown, John W.; Healy, Daniel P.; and
Sowinski, Kevin M., "Cefuroxime Pharmacokinetics in Pediatric Cardiovascular Surgery Patients Undergoing Cardiopulmonary
Bypass" (2011). Scholarship and Professional Work – COPHS. Paper 53.
http://digitalcommons.butler.edu/cophs_papers/53
Authors
Chad A. Knoderer, Sarah A. Saft, Scott G. Walker, Markl D. Rodefeld, Mark W. Turrentine, John W. Brown,
Daniel P. Healy, and Kevin M. Sowinski
This article is available at Digital Commons @ Butler University: http://digitalcommons.butler.edu/cophs_papers/53
Cefuroxime Pharmacokinetics in Pediatric Cardiovascular Surgery Patients Undergoing 
Cardiopulmonary Bypass 
 
C A Knoderer; S A Saft; S G Walker; M D Rodefeld; M W Turrentine; J W Brown; D P 
Healy; K M Sowinski 
Objectives 
The objective of this study was to determine the pharmacokinetics of cefuroxime in children undergoing 
cardiopulmonary bypass (CPB) for cardiovascular surgery.  
Design 
A prospective study.  
Setting 
A tertiary pediatric teaching hospital.  
Participants 
Infants and children undergoing CPB were enrolled in the study.  
Intervention 
An initial dose (mean, 24.2 ± 1.6 mg/kg) of cefuroxime was administered before surgical incision, and a 
second dose (mean, 14.4 ± 7.9 mg/kg) was administered in the CPB prime solution. Serial blood samples 
were obtained before, during, and after the CPB process. Samples were shipped on dry ice to the analytic 
laboratory and concentrations determined by a validated high-performance liquid chromatography 
method. A 2-compartment pharmacokinetic model was fitted to the data using maximum a priori–
Bayesian estimation, with weight as a covariate. Monte Carlo simulations of a single-dose (25 mg/kg pre-
CPB) approach and a 2-dose (25 mg/kg pre- and 12.5-mg/kg prime solution dose) approach were 
performed.  
Measurements and Main Results 
Fifteen subjects (9 males/6 females) were enrolled in the study, with median (range) age and weight of 11 
(3-34) months and 9.5 (4.5-15.4) kg, respectively. The median (range) duration of CPB was 136 (71-243) 
minutes. Median and range cefuroxime pharmacokinetic parameters were as follows: maximum 
concentration (Cmax) dose, 1: 328 (150-512) μg/mL; systemic clearance, 0.050 (0.041-0.058) L/h/kg; 
steady-state volume of distribution, 0.213 (0.081-0.423) L/kg; volume of distribution in the central 
compartment, 0.081 (0.046-0.162) L/kg; and elimination half-life, 3.76 (1.03-6.81) hours. The median 8-
hour post–dose-simulated cefuroxime concentrations were 26.5 and 16.0 mg/L for the 2-dose and single-
dose regimens, respectively.  
 
 
Conclusion 
Manufacturers recommend that pediatric doses of cefuroxime (25-50 mg/kg) can be used in infants and 
children undergoing CPB to maintain adequate serum concentrations for surgical-site infection 
prophylaxis. A second intraoperative dose, administered through the CPB circuit, provides no additional 
prophylactic advantage.  
Surgical-site infections (SSIs) account for approximately 16% of hospital-acquired infections. 
1
 
Of particular concern for patients undergoing cardiac surgery are deep sternal wound infections 
or mediastinitis after procedures with a median sternotomy. Sternal wound infections occur in 
5% of all children after median sternotomy. 
2
 Associated mortality is significant and has been 
reported to be as high as 60% in adults although there are little comparable data for children. 
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Estimates of sternal wound infections in pediatric patients after cardiac surgery vary from 3% for 
superficial sternal infections, 2% for deep sternal infections, to 0.04% to 3.9% for mediastinitis. 
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 Incidence of sternal wound infection has been shown to be greater in neonates (5.5%) versus 
older children (0.5%), and was associated with increased morbidity and mortality in the neonatal 
group. 
7
  
Incisional cellulitis and fever are common presenting signs of sternal wound infection in 
children. This likely is secondary to interruption of the skin barrier and further complicated by 
the placement of percutaneous devices that then may be colonized and potentially infected along 
the tract. In multiple series, staphylococcal species ( Staphylococcus aureus and Staphylococcus 
epidermidis ) were the most common infecting pathogens. 
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 For antimicrobial prophylaxis 
for cardiac surgery, a cephalosporin, such as cefazolin or cefuroxime, is the preferred agent 
unless a high probability of methicillin-resistant S aureus (MRSA) is suspected or the patient has 
a β-lactam allergy. 11 The minimum inhibitory concentration (MIC) value for staphylococcal 
species susceptible to parenteral cefuroxime is ≤8 μg/mL. 12  
A review of the literature shows limited pediatric data describing cardiopulmonary bypass (CPB) 
effects on prophylactic antibiotic therapy; none of which describes cefuroxime. 
13
 
14
 Children 
may have a greater hemodilution effect from CPB initiation than adults, and extrapolating from 
adult cefuroxime data creates inaccuracy. 
15
 Definitive recommendations for redosing of 
intraoperative antibiotic prophylaxis because of CPB effects are not available for children 
undergoing surgery for congenital heart defects. To adequately prevent SSI and subsequent 
morbidity and mortality, an additional intraoperative cefuroxime dose could be required if the 
cefuroxime serum concentration falls to below desired concentrations. The objective of this 
study was to determine the pharmacokinetics of cefuroxime in pediatric patients undergoing 
cardiac surgery with CPB. The authors also sought to evaluate whether doses currently used 
achieved appropriate concentrations for protection against potential pathogens.  
Methods 
Fifteen children between 1 month and 3 years of age who required CPB for their surgical repair 
were included. Subjects were excluded if they had an allergy to β-lactam antibiotics; were born 
at less than 36 weeks' gestational age or were older than 3 years (3 years and 0 days); had an 
anticipated CPB time of less than 30 minutes; or had a history of culture positive for MRSA, 
ventricular-assist device therapy, or cardiac transplantation. This study was conducted after 
approval from the institutional review board at Indiana University-Purdue University, 
Indianapolis, IN. Informed consent for the study was obtained from the parent or guardian at the 
time of surgical consent.  
Demographic data collected on all patients included sex, age, weight, serum creatinine, cardiac 
defect, and repair. Temperature, perfusion priming volume, time on CPB, coldest temperature, 
and modified ultrafiltration volume were collected from perfusion and anesthesia records. The 
contents of the CPB prime solution could vary per patient and contain, but were not limited to, 
plasmalyte, albumin, methylprednisolone, sodium bicarbonate, blood, and cefuroxime.  
Cefuroxime (target dose, 25 mg/kg) was administered through an intravenous catheter within 1 
hour before skin incision. A second dose of cefuroxime (target dose, 12.5 mg/kg) was 
administered in the CPB prime solution. Both doses were administered according to institutional 
standard. Seven serial blood samples were obtained before, during, and after CPB at the time 
points described in Table 1 . The times at which these samples were taken were targeted at the 
times described although the actual times varied depending on the clinical situation. The first 
sample was obtained by using excess blood from the routine baseline preoperative laboratory 
samples. The other blood samples (5 mL each) were obtained via arterial hemodynamic 
catheters, which all patients receive as a standard of cardiovascular surgical care, or directly from 
the CPB circuit (considered postcircuit). Blood samples were obtained by either the 
anesthesiologist or perfusionist while the patient remained in the operating room and by a 
pediatric intensive care unit nurse after surgery. Blood samples were collected into heparinized-
evacuated blood-collection tubes. Samples were mixed and centrifuged, and the plasma was 
collected and stored frozen at −70°C. Samples were shipped on dry ice to the analytic laboratory 
for analysis and processed within 4 weeks of receipt.  
Table 1 
Timing of Blood Samples for the Determination of Cefuroxime Pharmacokinetics 
Sample  Intraoperative Event  Approximate Time Relation to Cefuroxime Dosing  
1  Before cefuroxime dose  −12 to 72 hours  
2  Heparin administration  +70 minutes  
3  5 minutes after initiation of CPB  +90 minutes  
4  Initiation of rewarming  +180 minutes  
5  Separation from bypass  +210 minutes  
6  5 minutes after protamine administration  +230 minutes  
7  Arrival in the intensive care unit  +260 to 290 minutes  
Plasma concentrations of cefuroxime were determined by a modified reverse-phase high-
performance liquid chromatography method with ultraviolet detection (214 nm) per previously 
described techniques. 
16
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 Samples were processed by protein precipitation with 4% perchloric 
acid with tinidazole (10 μg/mL, Sigma, St. Louis, MO) used as the internal standard. Five 
hundred microliters of solution were added to 250 μL of sample, standard, or spiked control. The 
samples then were vortexed for 30 seconds followed by centrifugation at 3.0 g for 15 minutes. A 
50-μL portion of supernatant was injected directly onto the high-performance liquid 
chromatography column, and the peak-area ratio of cefuroxime-to-internal standard was 
analyzed. The only modification to the analytic procedure was the use of 2 Onyx monolithic C18 
analytic columns (50 × 4.6 mm) placed in series (Phenomenex, Torrance, CA). The range of 
assay linearity was 5.0 to 200 μg/mL ( r ≥ 0.998, n = 7); specimens with concentrations >200 
μg/mL were diluted with blank pooled human plasma and reassayed. The limit of assay detection 
with a 50-μL injection volume was 1.0 μg/mL. The within-day (n = 5) and between-day (n = 7) 
coefficients of variation for spiked control specimens (5, 50, and 200 μg/mL) were ≤3.4% and 
≤8.2%, respectively.  
Initial estimates of cefuroxime pharmacokinetics were determined by noncompartmental 
techniques using the individual concentration-time data. After visualizing the concentration-time 
profile and the 2-exponential decline characteristics, a 2-compartment model was chosen as the 
structural pharmacokinetic model. Equations describing a 2-compartment, pharmacokinetic 
model were fitted to each subject's cefuroxime concentration-time data using ADAPT 5 
18
 with 
the weighted least-squares estimator. The pharmacokinetic parameters estimated were as 
follows: Vc, the apparent volume of distribution in the central compartment; Vp, the apparent 
volume of distribution in the peripheral compartment; Cld, the distribution clearance between the 
central and peripheral compartment; and Cls, systemic clearance, which was assumed not to 
change over the course of the entire study period. The weighting scheme used was 1/(observed 
concentration) 
2
 . After completion of the initial weighted least-squares fitting process, the 
impact of weight as a coavariate on pharmacokinetics was investigated. The authors observed a 
significant relationship between weight and pharmacokinetic parameters. The same structural 
model was fit to the data this time using the maximum a priori (MAP)-Bayesian estimator in 
ADAPT 5. The initial pharmacokinetic parameter estimates with their associated intersubject 
variability were used as initial MAP-Bayesian estimators, with Vc and Cls normalized for 
subject weight. The variance model assumed the standard deviation of the residuals was linear 
with increasing concentrations using the following equation: f(V) = [y int + m(y)] 
2
 , where y int is 
the y-intercept of the residual plot and m is the slope of the line. The y-intercept was fixed at 
one-half of the lower limit of detection for the cefuroxime assay. The slope (m) was estimated in 
each individual subject. The same pimary pharmacokinetic parameters were estimated with this 
model. The secondary parameters estimated in this model were apparent steady-state volume of 
distribution (Vss), elimination rate constant, and elimination half-life (t1/2). Secondary 
parameters were calculated by standard equations. Model fits were assessed by visual inspection 
of the predicted versus measured data and the distribution of the weighted residuals.  
One hundred simulations were performed using the MAP-Bayesian–generated pharmacokinetic 
estimates using 2 dosing schemes: (1) an initial 25-mg/kg intravenous dose followed by a 12.5-
mg/kg prime dose (study dose), and (2) an initial 25-mg/kg intravenous dose. Each simulation 
consisted of using the mean and variance of the pharmacokinetic parameters (Vc, Vp, Cls, and 
Cld) from the final pharmacokinetic analysis as described previously, with the parameters listed 
in Table 2 .  
 
 
 
Table 2 
Subject Demographics 
Subject  Sex  RACHS  
Minimal 
Temperature 
(°C)  
Age 
(Months)  
Dose 1 
(mg/kg)  
Dose 2 
(mg/kg)  
Pre-
weight 
(kg)  
Post-
weight 
(kg)  
Height 
(cm)  
Prime 
Vol 
(mL)  
Duration of 
CPB (min)  
1  M  3  28  19  24.8  6.76  11.1  11.1  81  830  124  
Subject  Sex  RACHS  
Minimal 
Temperature 
(°C)  
Age 
(Months)  
Dose 1 
(mg/kg)  
Dose 2 
(mg/kg)  
Pre-
weight 
(kg)  
Post-
weight 
(kg)  
Height 
(cm)  
Prime 
Vol 
(mL)  
Duration of 
CPB (min)  
2  M  2  28  17  24.3  14.6  10.3  10.3  71  570  125  
3  M  3  27  4.5  23.2  12.5  5.3  5.4  65  515  168  
4  F  3  26.6  11  26.7  None  7.9  9.0  72  600  165  
5  F  3  28  18  22.1  11.5  10.6  11.3  85  565  151  
6  M  3  30  27  25.4  12.3  13.6  13.8  92  825  75  
7  F  2  26.1  9  23.8  11.9  8.4  8.4  76  620  163  
8  M  4  25  9  24.2  12.1  8.7  9.1  67  715  405  
9  M  4  28  10  23.6  28.3  10  10.6  76  450  93  
11  F  3  28  23  27.0  12.6  10.2  10.2  81  675  154  
12  M  3  30  11  25.6  12.6  7.8  7.8  74  630  124  
13  F  4  26  12  23.3  29.1  9.5  10.3  74  1000  107  
14  F  3  27  6  23.7  27.0  7.1  7.4  66  650  108  
15  M  3  26  3  20.9  11.5  4.5  4.8  62  670  120  
16  M  3  29  33.6  24.4  12.7  15.4  15.4  94  770  93  
  
Mean  27.5  14.2  24.2  14.4  9.36  9.66  75.7  672.3  145  
  
SD  1.5  8.65  1.59  7.94  2.83  2.80  9.51  139.7  77.5  
  
Median  28  11.0  24.2  12.5  9.50  10.2  74.0  650  124  
Demographic study data were collected and reported by descriptive statistics. Regression 
analysis was used to determine the relationship between weight and the initial pharmacokinetic 
parameter fits. Statistical analysis was performed using Graph Pad Prism (v 5.2; Graph Pad 
Software Inc., La Jolla, CA). Statistical significance was defined as a p value of <0.05.  
Results 
Sixteen subjects provided informed consent and were enrolled. Because of a protocol violation, 
15 subjects (9 male subjects and 6 female subjects) completed the study. The subject 
demographics are shown in Table 2 . As shown in Table 2 , all but 1 subject received 2 doses of 
cefuroxime. No adverse effects were reported related to cefuroxime.  
The mean cefuroxime pharmacokinetic parameters are shown in Table 3 . Individual cefuroxime 
plasma concentration-time curves, both observed and modeled data, in 6 representative subjects 
are shown in Figure 1 . As evidenced by this figure, there was good agreement between the fitted 
and observed data. The simulated cefuroxime concentration-time curves for the 2 cefuroxime 
dosing regimens are shown in Figure 2 . Median 8-hour postdose-simulated cefuroxime 
concentrations were 26.5 and 16.0 mg/L for the 2-dose and single-dose regimens, respectively.  
 Fig 1 
Representative individual observed and modeled cefuxoxime concentration-time curves in 6 subjects. Observed data are 
indicated by the closed circles and modeled data by the solid lines. Subjects 3, 7, and 12 were younger than 1 year of age and 
subjects 5, 13, and 16 were older than 1 year of age. 
 
 
 
Fig 2 
Simulated cefuroxime mean concentration-time profiles for 2 dosing regimens, a 25-mg/kg single dose (closed circles, solid line) 
and a 25-mg/kg initial dose followed by 12.5 mg/kg dose in the CPB prime solution (open boxes, dotted line). 
Table 3  
Mean and Standard Deviation (SD) Cefuroxime Pharmacokinetic Parameters 
 
Mean  SD  
Cld (mL/min/kg)  43.9  40.2  
Cls (mL/min/kg)  11.8  4.79  
Vp (L/kg)  8.08  4.49  
Vc (L/kg)  8.53  3.72  
Vss (L/kg)  0.2104  0.0605  
t½ (h)  19.1  3.51  
β (h)  0.037  0.006  
Cmax 1st dose (μg/mL)  328  102  
Discussion 
Cefuroxime is the preferred prophylactic antibiotic for pediatric cardiovascular surgery at the 
authors' institution. The initial dose is administered within 60 minutes of incision, and, in 
accordance with Surgical Infection Prevention (SIP) project and Society of Thoracic Surgeons 
(STS) recommendations, redosing is considered for procedures past 4 hours in length, regardless 
of the use of CPB. 
11
 
19
 However, there are no published data regarding cefuroxime 
pharmacokinetics during pediatric cardiac surgeries requiring CPB and no pediatric-specific 
recommendations for the redosing of cefuroxime in these procedures. Pharmacokinetic 
differences observed in children when compared with adults make extrapolating adult literature 
difficult. 
20
  
CPB is a multiphased process with potential to alter the pharmacokinetic properties of a variety 
of medications including antibiotics. 
15
 
21
 Prolonged CPB time has been linked to increased 
infection risk, thus making optimization of antibiotic prophylaxis critical. 
2
 
22
 Caffarelli et al 
showed inadequate cefazolin serum concentrations after single prophylactic cefazolin doses for 
cardiac surgeries requiring longer than 120 minutes on CPB. 
23
 In the present study population, 
the average time on CPB was 145 minutes, making this an important factor. CPB-related 
hemodilution, as a result of the administration of blood and primer solution, decreases total 
serum concentration of medications through altering the volume of distribution of drugs. 
26
 
27
 
This effect has been shown with cephalosporins. 
24
 
25
 Cefazolin concentrations decrease 32% to 
62% as a result of the hemodilution effects of CPB. 
14
 
26
  
Multiple studies have investigated the pharmacokinetics of cefuroxime during CPB although 
none has been performed in children, making comparison to the present results difficult. 
16
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28
 
29
 
However, it appears through the findings of Nascimento et al and Vuorisalo et al that cefuroxime 
pharmacokinetics in adults undergoing CPB are not altered by CPB. 
27
 
29
 The present findings in 
children are similar in that CPB does not appear to alter cefuroxime pharmacokinetics. 
Alternative cefuroxime dosing regimens, such as continuous infusion cefuroxime, have been 
studied in adults undergoing cardiac surgery, but making extrapolation to children is difficult 
because of the differences in dosing. 
16
  
Patients with congenital heart defects are a uniquely ill population with generally immature 
immune systems. 
7
 Children less than 1 year of age are the largest group undergoing surgery for 
congenital heart lesions. Fragility in the infant and postoperative period likely contribute to 
making deep sternal wound infections a life-threatening complication in this population. 
Additionally, infants requiring CPB may undergo deep hypothermic circulatory arrest resulting 
in decreased immune function. 
30
 Blunting of the immune response also may occur secondary to 
prolonged periods of diminished cardiac output. 
31
 Children with prolonged CPB time, long 
aortic cross-clamp time, long total operation time, and high-body-mass index have an increased 
risk for developing SSIs. 
22
 
32
 Optimizing the pharmacodynamic properties of perioperative 
antibacterial regimens is imperative to prevent infection.  
The only study to examine cephalosporin pharmacokinetics in children undergoing CPB used 
cefazolin with gentamicin in infants less than 10 kg. 
14
 The investigators found that cefazolin 
distribution volume and elimination are altered by CPB, but that their dosing regimen (35 mg/kg) 
used, which is slightly higher than the recommended dosing range, remained effective for 
optimal infection prevention. 
1
 
33
 Comparing the present findings with those of Haessler et al 
14
 is 
difficult given the inherent differences in pharmacokinetic profiles between cefazolin and 
cefuroxime. Cefazolin is much more highly protein bound than cefuroxime. 
34
 Hemodilution-
related decreases in circulating plasma proteins, specifically albumin and α-acid glycoprotein, 
may result in increased free drug and redistribution of drug to tissues as a result of CPB, and may 
lead to an overall increased free fraction of cefazolin. 
21
 
24
 This may not be applicable to 
cefuroxime given the minimal protein binding as compared with cefazolin.  
In general, maximum bacterial killing for cephalosporins is observed when serum concentrations 
(unbound drug) are maintained above the MIC for 60% to 70% of the dosing interval, although a 
lower percentage may be required for staphylococcal species. 
35
 Cephalosporins, such as 
cefuroxime, are preferred antimicrobials for prophylaxis after cardiac surgery, in part because of 
the activity against S aureus and S epidermis . 
11
 The median 8-hour postdose-simulated 
cefuroxime concentrations were 26.5 and 16.0 mg/L for the 2-dose and single-dose regimens, 
respectively. Given the protein binding of cefuroxime of approximately 30%, either a 2-dose or 
single-dose intraoperative regimen would result in a serum concentration above the MIC for 
staphylococcal species for 100% of the dosing interval based on when the postoperative regimen 
would be the initiated model. 
34
 It appears as though a second intraoperative dose, administered 
through the CPB circuit, provides no additional prophylactic advantage. Currently, the 
manufacturer's recommended pediatric doses of cefuroxime (25-50 mg/kg) can be used in infants 
and children undergoing CPB to maintain adequate serum concentrations for SSI prophylaxis.  
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